1.Comparision of Health Behaviors, Diabetes Mellitus(DM) Management and Health-related Quality of Life(HRQoL) between DM Groups with and without Diabetic Education Experience.
Journal of Agricultural Medicine & Community Health 2018;43(2):85-96
PURPOSE: This study was to compare health behaviors, DM management and HRQoL among Diabetic patients according to education experience. METHODS: Data were obtained from Community health Survey(CHS) of 2015. The participants were 22,937 diabetic patients who had education experience or not. Data were analyzed on complex sample anaysis using SPSS 24 program. RESULTS: The education experience group showed higher percentages of health behaviors and DM Management and higher HRQoL. The significant negative factors influencing HRQoL were Bed ridden experience, higher subjective stress, depression expereince, age, low education and positive factors were good subjective health status, walking, mod-exercise, drinking, employment, spouse, good subjective happiness. CONCLUSION: These results show that education experience is a way to help diabetic patients' health behavior, DM management, HRQoL.
Depression
;
Diabetes Mellitus
;
Diagnostic Self Evaluation
;
Drinking
;
Education*
;
Employment
;
Happiness
;
Health Behavior*
;
Humans
;
Spouses
;
Walking
2.The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
Min Joo KIM ; Seung hyun BAEK ; Sanghwa KO
Korean Journal of Clinical Oncology 2018;14(2):116-119
PURPOSE: This study assessed the effect of chemotherapy over stage II colon cancer in terms of presence of high-risk factors.METHODS: Data were retrospectively reviewed for 364 patients with stage II colon cancer who underwent curative surgery between January 2007 and December 2012. High-risk factors of stage II colon cancer were examined, and the overall survival (OS) rates were analyzed. Survival benefit of adjuvant chemotherapy was also analyzed.RESULTS: One hundred and fifteen cases had exclusively single high-risk factor and 194 cases were negative for high-risk factors. Postoperative chemotherapy was performed in 262 of 364 patients (72.0%). The 5-year OS was 79.4% and 86.6% for patients without adjuvant chemotherapy and those with chemotherapy, respectively. The 5-year OS was 88.2% and 83.3% for patients having exclusively single high-risk factor with adjuvant chemotherapy and those without chemotherapy, respectively.CONCLUSION: Adjuvant chemotherapy for patients with stage II colon cancer having exclusively single high-risk factor could be omitted, weighing up the survival benefit and side effect of chemotherapy.
Chemotherapy, Adjuvant
;
Colon
;
Colonic Neoplasms
;
Colorectal Neoplasms
;
Drug Therapy
;
Humans
;
Retrospective Studies
;
Survival Analysis
3.Preoperative Magnetic Resonance Imaging and Survival Outcomes in T1–2 Breast Cancer Patients Who Receive Breast-Conserving Therapy.
Jaegyu RYU ; Hyung Seok PARK ; Sanghwa KIM ; Jee Ye KIM ; Seho PARK ; Seung Il KIM
Journal of Breast Cancer 2016;19(4):423-428
PURPOSE: The purpose of the study was to evaluate the effect of preoperative magnetic resonance imaging (MRI) on survival outcomes for breast cancer. METHODS: A total of 954 patients who had T1–2 breast cancer and received breast-conserving therapy (BCT) between 2007 and 2010 were enrolled. We divided the patients according to whether they received preoperative MRI or not. Survival outcomes, including locoregional recurrence-free survival (LRRFS), recurrence-free survival (RFS), and overall survival (OS), were analyzed. RESULTS: Preoperative MRI was performed in 743 of 954 patients. Clinicopathological features were not significantly different between patients with and without preoperative MRI. In the univariate analyses, larger tumors were marginally associated with poor LRRFS compared to smaller tumors (hazard ratio [HR], 3.22; p=0.053). Tumor size, histologic grade, estrogen receptor (ER), progesterone receptor (PR), hormonal therapy, and adjuvant chemotherapy status were associated with RFS. Larger tumor size, higher histologic grade, lack of ER and PR expression, and no hormonal therapy were associated with decreased OS. Tumor size was associated with LRRFS in the multivariate analyses (HR, 4.19; p=0.048). However, preoperative MRI was not significantly associated with LRRFS, RFS, or OS in either univariate or multivariate analyses. CONCLUSION: Preoperative MRI did not influence survival outcomes in T1–2 breast cancer patients who underwent BCT. Routine use of preoperative MRI in T1–2 breast cancer may not translate into longer RFS and OS.
Breast Neoplasms*
;
Breast*
;
Chemotherapy, Adjuvant
;
Estrogens
;
Humans
;
Magnetic Resonance Imaging*
;
Mastectomy, Segmental
;
Multivariate Analysis
;
Receptors, Progesterone
4.Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
Sanghwa KIM ; Hyung Seok PARK ; Jee Ye KIM ; Jegyu RYU ; Seho PARK ; Seung Il KIM
Yonsei Medical Journal 2016;57(5):1192-1198
PURPOSE: The optimum local surgical strategy regarding breast-conserving therapy (BCT) for triple-negative breast cancer (TNBC) is controversial. To investigate whether BCT is appropriate for patients with TNBC, we evaluated the clinical outcomes of BCT in women with TNBC compared to those of women without TNBC, using a large, single-center cohort. MATERIALS AND METHODS: We performed a retrospective analysis of 1533 women (TNBC n=321; non-TNBC n=1212) who underwent BCT for primary breast cancer between 2000 and 2010. Clinicopathological characteristics, locoregional recurrence-free survival (LRFS), and overall survival (OS) were analyzed. RESULTS: Tumors from the TNBC group had a higher T stage (T2 37.4% vs. 21.0%, p<0.001), a lower N stage (N0 86.9% vs. 75.5%, p<0.001), and a higher histologic grade (Grade III 66.8% vs. 15.4%, p<0.001) than the non-TNBC group. There were no differences in 5-year LRFS rates between the TNBC and non-TNBC groups (98.7% vs. 97.8%, p=0.63). The non-TNBC group showed a slightly better 5-year OS than the TNBC group; however, the difference was not significant (96.2% vs. 97.3%, p=0.72). In multivariate analyses, TNBC was not associated with poor clinical outcomes in terms of LRFS and OS [hazard ratio (HR) for LRFS=0.37, 95% confidence interval (CI): 0.10-1.31; HR for OS=1.03, 95% CI: 0.31-3.39]. CONCLUSION: TNBC patients who underwent BCT showed non-inferior locoregional recurrence compared to non-TNBC patients with BCT. Thus, BCT is an acceptable surgical approach in patients with TNBC.
Adult
;
Aged
;
Breast Neoplasms/mortality/pathology/*surgery
;
Disease-Free Survival
;
Female
;
Humans
;
*Mastectomy, Segmental
;
Middle Aged
;
*Neoplasm Recurrence, Local/mortality/pathology
;
Proportional Hazards Models
;
Retrospective Studies
;
Time Factors
;
Treatment Outcome
;
Triple Negative Breast Neoplasms/mortality/pathology/*surgery
5.Gingival absorption of α-tocopherol acetate and 18β-glycyrrhetinic acid : in vitro evaluation in reconstructed gingival tissue.
Yun Sun KIM ; Ju Ae KIM ; Aram YOU ; Hosong CHO ; Jae Young SHIN ; Sanghwa LEE
Journal of Korean Academy of Oral Health 2016;40(2):79-84
OBJECTIVES: To assess the absorption of α-tocopherol acetate and 18β-glycyrrhetinic acid, which are used as active ingredients in toothpaste, into a reconstructed gingival tissue. METHODS: EpiGingival™ tissues were treated with a 25% slurry of toothpaste containing 2% α-tocopherol acetate and 0.3% 18β-glycyrrhetinic acid, for 2 minutes. The treatment was repeated up to 6 times, with 1 hour intervals. After completion of all treatments, the active ingredients in the tissue extracts and receiver solutions were measured by high performance liquid chromatography. RESULTS: Although α-tocopherol acetate was not detected, α-tocopherol was detected in the tissue extracts, indicating that α-tocopherol acetate was bioconverted to α-tocopherol after absorption. We could detect 18β-glycyrrhetinic acid both in the tissue extracts and in the receiver solutions, with a positive correlation to the number of treatments. CONCLUSIONS: We found that our toothpaste effectively delivered α-tocopherol acetate and 18β-glycyrrhetinic acid to a reconstructed gingival tissue in vitro.
Absorption*
;
Chromatography, Liquid
;
In Vitro Techniques*
;
Periodontal Diseases
;
Tissue Extracts
;
Toothpastes
6.Frozen Sections in Decision-Making Regarding the Axillary Procedures in Breast Conserving Surgery for Intraductal Carcinoma at Preoperative Diagnosis
Sanghwa KIM ; Kwanbum LEE ; Mushabab Ali ALSHAHRANI ; Jee Hyun AHN ; Jeea LEE ; Hyung Seok PARK
Journal of Korean Medical Science 2023;38(30):e224-
Background:
Axillary evaluation is unnecessary for pure ductal carcinoma in situ (DCIS);however, it is performed because of the risk of upstaging to invasive cancer. We assessed the role of intraoperative frozen section (IOF) biopsy in reducing invasive cancer upstaging and axillary evaluation in preoperative DCIS patients.
Methods:
We reviewed patients with preoperative DCIS who underwent breast-conserving surgery (BCS) with IOF biopsy. Positive IOF biopsy findings were defined as the presence of invasive or micro-invasive cancer. The IOF biopsy and permanent pathology findings were compared.
Results:
Seventy-eight patients underwent BCS with IOF biopsy. Six patients showed positive IOF biopsy findings; five of these patients showed concordant permanent pathology findings.Sentinel lymph node biopsy (SLNB) was positive in one patient. Thirteen patients with invasive breast cancer were missed by IOF biopsy; they underwent SLNB during the second surgery. None of them had metastatic lymph nodes. The sensitivity and specificity of IOF biopsy were 27.7% and 98.3%, respectively, with 82.1% accuracy. None of the other factors showed statistically significant relationships with the permanent pathology findings, except for the IOF biopsy findings.
Conclusion
IOF evaluation can aid in detecting the invasiveness of tumors in patients with preoperative DCIS.
7.Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results.
Hyung Seok PARK ; Seo Jin PARK ; Jee Ye KIM ; Sanghwa KIM ; Jaegyu RYU ; Joohyuk SOHN ; Seho PARK ; Gun Min KIM ; In Sik HWANG ; Jong Rak CHOI ; Seung Il KIM
Annals of Surgical Treatment and Research 2017;92(5):331-339
PURPOSE: We evaluated the clinical role of rapid next-generation sequencing (NGS) for identifying BRCA1/2 mutations compared to traditional Sanger sequencing. METHODS: Twenty-four paired samples from 12 patients were analyzed in this prospective study to compare the performance of NGS to the Sanger method. Both NGS and Sanger sequencing were performed in 2 different laboratories using blood samples from patients with breast cancer. We then analyzed the accuracy of NGS in terms of variant calling and determining concordance rates of BRCA1/2 mutation detection. RESULTS: The overall concordance rate of BRCA1/2 mutation identification was 100%. Variants of unknown significance (VUS) were reported in two cases of BRCA1 and 3 cases of BRCA2 after Sanger sequencing, whereas NGS reported only 1 case of BRCA1 VUS, likely due to differences in reference databases used for mutation identification. The median turnaround time of Sanger sequencing was 22 days (range, 14–26 days), while the median time of NGS was only 6 days (range, 3–21 days). CONCLUSION: NGS yielded comparably accurate results to Sanger sequencing and in a much shorter time with respect to BRCA1/2 mutation identification. The shorter turnaround time and higher accuracy of NGS may help clinicians make more timely and informed decisions regarding surgery or neoadjuvant chemotherapy in patients with breast cancer.
Breast Neoplasms*
;
Breast*
;
Clinical Decision-Making*
;
Drug Therapy
;
High-Throughput Nucleotide Sequencing
;
Humans
;
Methods
;
Prospective Studies
8.Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers.
Janghee LEE ; Seho PARK ; Sanghwa KIM ; Jeeye KIM ; Jegyu RYU ; Hyung Seok PARK ; Seung Il KIM ; Byeong Woo PARK
Yonsei Medical Journal 2015;56(5):1213-1220
PURPOSE: Newly developed extra-mammary multiple primary cancers (MPCs) are an issue of concern when considering the management of breast cancer survivors. This study aimed to investigate the prevalence of MPCs and to evaluate the implications of MPCs on the survival of breast cancer patients. MATERIALS AND METHODS: A total of 8204 patients who underwent surgery at Severance Hospital between 1990 and 2012 were retrospectively selected. Clinicopathologic features and survival over follow-up periods of < or =5 and >5 years were investigated using univariate and multivariate analyses. RESULTS: During a mean follow-up of 67.3 months, 962 MPCs in 858 patients (10.5%) were detected. Synchronous and metachronous MPCs were identified in 23.8% and 79.0% of patients, respectively. Thyroid cancer was the most prevalent, and the second most common was gynecologic cancer. At < or =5 years, patients with MPCs were older and demonstrated significantly worse survival despite a higher proportion of patients with lower-stage MPCs. Nevertheless, an increased risk of death in patients with MPCs did not reach statistical significance at >5 years. The causes of death in many of the patients with MPCs were not related to breast cancer. Stage-matched analysis revealed that the implications of MPCs on survival were more evident in the early stages of breast disease. CONCLUSION: Breast cancer patients with MPCs showed worse survival, especially when early-stage disease was identified. Therefore, it is necessary to follow screening programs in breast cancer survivors and to establish guidelines for improving prognosis and quality of life.
Adult
;
Aged
;
Breast/pathology
;
Breast Neoplasms/diagnosis/*mortality
;
Female
;
Humans
;
Middle Aged
;
Multivariate Analysis
;
Neoplasm Metastasis
;
Neoplasm Staging
;
Neoplasms, Multiple Primary/diagnosis/*mortality
;
Neoplasms, Second Primary/diagnosis/*mortality
;
Prognosis
;
*Quality of Life
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Survival Analysis
9.Changes in levels of fractional exhaled and nasal nitric oxide after treatment in allergic rhinitis
Sanghwa HONG ; Chae-Gu JO ; Hyuna KIM ; Young-Seok LEE ; Woo Yong BAE ; Jin-A JUNG
Allergy, Asthma & Respiratory Disease 2022;10(3):153-157
Purpose:
Recent studies have reported that nasal nitric oxide (NO) increases in patients with allergic rhinitis (AR) and bronchial asthma (BA), and can be used as a noninvasive test to determine treatment efficacy. We aimed to investigate the changes in fractional exhaled NO (FeNO) and nasal NO levels before and after treatment in patients with AR and asthma.
Methods:
Children aged 6–18 years who visited Dong-A University Hospital from August 2013 to July 2014 were treated for mildpersistent or severe-intermittent AR according to Allergic Rhinitis and its Impact on Asthma guidelines. FeNO and nasal NO were measured using NObreath. Among all patients, rhinitis was treated for 1 month, and the results were evaluated in patients with improved AR (n = 31), improved AR+BA (n = 23), and control (n = 19) groups.
Results:
Sex, age, body mass index, allergy, serum total eosinophil count and immunoglobulin E, erythrocyte sedimentation rate, and C-reactive protein showed no intergroup differences before or after treatment. Nasal NO before treatment was higher in the BA+AR and AR groups than controls (P = 0.005), but there was no difference between disease groups after treatment. Both groups showed a significant decrease in nasal NO after treatment compared with measurements before treatment (AR, P = 0.044; AR+BA, P = 0.004).
Conclusion
Nasal NO can be effectively used as a noninvasive test for clinical efficacy because it was significantly reduced by improving symptoms in AR patients with and without asthma.
10.An Updated Nomogram for Predicting Invasiveness in Preoperative Ductal Carcinoma In Situ of the Breast
Sanghwa KIM ; Jihong KIM ; Hyung Seok PARK ; Ha Yan KIM ; Kwanbum LEE ; Jeea LEE ; Haemin LEE ; Jee Ye KIM ; Seung Il KIM ; Young Up CHO ; Byeong Woo PARK
Yonsei Medical Journal 2019;60(11):1028-1035
PURPOSE: To validate and update a nomogram for predicting ductal carcinoma in situ (DCIS) upstaging in preoperative biopsy. MATERIALS AND METHODS: Medical records of 444 preoperative DCIS patients were evaluated and used to validate a previous version of the Severance nomogram for predicting DCIS upstaging in preoperative biopsy. Patients were divided into two groups according to the final postoperative pathology. Univariate and multivariate analyses with the chi-square test, Student's t-test, and binary logistic regression method identified new significant variables. The updated nomogram was evaluated with the C-index and Hosmer—Lemeshow goodness of fit test. RESULTS: The area under a receiver operating characteristic curve for comparison with the previous nomogram was 0.48. In postoperative pathology, the pure DCIS and invasive cancer groups comprised 345 and 99 cases, respectively. Approximately 22.3% of patients preoperatively diagnosed with DCIS were upstaged to invasive cancer. Significant variables in the univariate analysis were operation type, human epidermal growth factor receptor 2 overexpression, comedo necrosis, sonographic mass, mammographic mass, preoperative biopsy method, and suspicious microinvasion in preoperative biopsy. In multivariate analysis, operation type, sonographic mass, mammographic mass, and suspicious microinvasion were risk factors for upstaging. The updated model with these variables showed moderate discrimination and was appropriate in the calibration test. CONCLUSION: The previous nomogram did not effectively discriminate upstaging of preoperative DCIS in an independent cohort. An updated version of the nomogram appears to provide more accurate information for predicting preoperative DCIS upstaging.
Biopsy
;
Breast Neoplasms
;
Breast
;
Calibration
;
Carcinoma, Ductal
;
Carcinoma, Intraductal, Noninfiltrating
;
Cohort Studies
;
Discrimination (Psychology)
;
Humans
;
Logistic Models
;
Medical Records
;
Methods
;
Multivariate Analysis
;
Necrosis
;
Nomograms
;
Pathology
;
Receptor, Epidermal Growth Factor
;
Risk Factors
;
ROC Curve
;
Ultrasonography